Simon Lange

Simon’s experience includes advising:

LBOs

• One Rock Capital Partners in its acquisition of Europe Snacks
• PSG Equity in its acquisition of Diapason
• Summit Partners in its acquisition of Doctrine
• Astorg in its acquisition of:
  • IPCOM
  • CordenPharma
  • Corialis
  • Nemera
• Bridgepoint in:
  • its acquisition of LumApps
  • its acquisition of Nexity SA’s residential property management services business
  • its acquisition of Spartfin Group
  • in the sale of eFront
• Ardian in the sale of Unither Pharmaceuticals
• KKR:
  • in its acquisition of Elsan
  • in the €2.4 billion sale of Webhelp
• Ardian Expansion in its acquisition of Syclef
• Permira in its minority investment in Safti
• Platinum Equity in its acquisition of:
  • Solo Group
  • Biscuit International
• The founders and TA Associates in the acquisition of Babilou by Antin Infrastructure Partners

Private M&A

• Tradesy in its acquisition by Vestiaire Collective
• Doctrine in its acquisition of:
  • Predictice
  • Maite.ai
• Lumapps in its acquisition of Beekeeper
• Biscuit International in its acquisition of Continental Bakeries
• Elsan in its acquisition of Groupe C2S
• Albéa in the sale of its dispensing business to Silgan
• Burger King in its sale of Quick
• Fraikin in its acquisition of VIA Location

Public M&A

• Bridgepoint in its public tender offer for Esker
• Calliditas in its acquisition of a controlling interest in Genkyotex
• TechnipFMC in the context of a planned spinoff transaction to separate into two industry-leading, independent, publicly traded companies

Venture Capital

• Astorg Philanthropy Investments (API) in the €11 million Series A funding round of InHeart
• General Catalyst on the €385 million Series A, €600 million Series B and €1.7 billion Series C funding rounds of Mistral AI
• Goldman Sachs Alternatives as lead investor on the US$55 million Series B funding round of 73 Strings
• Lazard Elaia Capital on the US$100 million funding round of DentalMonitoring
• Leonard Green & Partners on the €64 million Series B funding round of TreeFrog Therapeutics
• Vitruvian on the €60 million Series B funding round of Singulart